Evidence map›Paper›PMID 26497552›Full record

ArticleOncotarget2015

Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression.

Zlatko Kopecki, Gink N Yang, Jessica E Jackson, Elizabeth L Melville, Matthew P Calley, Dedee F Murrell, Ian A Darby, Edel A O'Toole, Michael S Samuel, Allison J Cowin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Overexpression ofInternational journal of molecular sciences · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Zlatko KopeckiRegenerative Medicine, Future Industries Institute, University of South Australia, Adelaide, South Australia, Australia.
Gink N YangRegenerative Medicine, Future Industries Institute, University of South Australia, Adelaide, South Australia, Australia.
Jessica E JacksonRegenerative Medicine, Future Industries Institute, University of South Australia, Adelaide, South Australia, Australia.
Elizabeth L MelvilleRegenerative Medicine, Future Industries Institute, University of South Australia, Adelaide, South Australia, Australia.
Matthew P CalleyCentre for Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Dedee F MurrellDepartment of Dermatology, St. George Hospital and University of New South Wales, Sydney, New South Wales, Australia.
Ian A DarbySchool of Medical Sciences, RMIT University, Melbourne, Victoria, Australia.
Edel A O'TooleCentre for Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Michael S SamuelCentre for Cancer Biology, an alliance between SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
Allison J CowinRegenerative Medicine, Future Industries Institute, University of South Australia, Adelaide, South Australia, Australia.
University of South Australia · AUQueen Mary University of London · GBCentre for Cancer Biology · AURMIT University · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flightless I (Flii) is an actin remodeling protein that affects cellular processes including adhesion, proliferation and migration. In order to determine the role of Flii during carcinogenesis, squamous cell carcinomas (SCCs) were induced in Flii heterozygous (Flii+/-), wild-type and Flii overexpressing (FliiTg/Tg) mice by intradermal injection of 3-methylcholanthrene (MCA). Flii levels were further assessed in biopsies from human SCCs and the human SCC cell line (MET-1) was used to determine the effect of Flii on cellular invasion. Flii was highly expressed in human SCC biopsies particularly by the invading cells at the tumor edge. FliiTg/Tg mice developed large, aggressive SCCs in response to MCA. In contrast Flii+/- mice had significantly smaller tumors that were less invasive. Intradermal injection of Flii neutralizing antibodies during SCC initiation and progression significantly reduced the size of the tumors and, in vitro, decreased cellular sphere formation and invasion. Analysis of the tumors from the Flii overexpressing mice showed reduced caspase I and annexin V expression suggesting Flii may negatively regulate apoptosis within these tumors. These studies therefore suggest that Flii enhances SCC tumor progression by decreasing apoptosis and enhancing tumor cell invasion. Targeting Flii may be a potential strategy for reducing the severity of SCCs.

Indexed as

AnimalsApoptosisCarcinoma, Squamous CellCarrier ProteinsCytoskeletal ProteinsDisease ProgressionFemaleHeterograftsHumansMiceMice, Inbred BALB CMicrofilament ProteinsReceptors, Cytoplasmic and NuclearSkin NeoplasmsTrans-ActivatorsCarrier ProteinsCytoskeletal ProteinsFLII protein, humanFlII protein, mouseMicrofilament ProteinsReceptors, Cytoplasmic and NuclearTrans-Activatorscell invasionFlightlessskin cancersquamous cell carcinoma

Identifiers

PMID26497552
PMCPMC4742187
OpenAlexW1892711524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.